AIGH Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

AIGH Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	+1,200,000	New	+$10.8M	1.53%	20
2025 Q4	–	Sell	-1,231,932	Closed	-$11.7M	–	45
2025 Q3	$11.7M	Buy	1,231,932 +313,039	+34%	+$3.14M	3.3%	11
2025 Q2	$8.1M	Sell	918,893 -519,216	-36%	-$4.21M	3.64%	11
2025 Q1	$10.8M	Buy	1,438,109 +649,495	+82%	+$5.16M	4.46%	7
2024 Q4	$6.58M	Buy	+788,614	New	+$6.73M	2.06%	19
2024 Q3	–	Sell	-181,673	Closed	-$890K	–	47
2024 Q2	$890K	Buy	+181,673	New	+$861K	0.28%	31

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AIGH Capital Management's ZVRA Position: Q1 2026 in Review

AIGH Capital Management opened a new position in Zevra Therapeutics (ZVRA) in Q1 2026: 1,200,000 shares worth $11.2M. The stake represents 1.53% of the portfolio and ranks #20 among its holdings. This is a return to the name: AIGH Capital Management previously reported a position in ZVRA as recently as Q3 2025.

AIGH Capital Management first reported a position in ZVRA in Q2 2024 and has held it in 6 quarters since. The position peaked at $11.7M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

AIGH Capital Management held 1,200,000 shares of Zevra Therapeutics worth $11.2M as of Q1 2026.
Zevra Therapeutics was a new AIGH Capital Management position in Q1 2026.
Zevra Therapeutics made up 1.53% of AIGH Capital Management's portfolio in Q1 2026, its #20 holding.
AIGH Capital Management first reported a position in Zevra Therapeutics in Q2 2024 and has held it in 6 quarters since.
AIGH Capital Management's Zevra Therapeutics position peaked at $11.7M in Q3 2025.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.